{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:46:15Z","timestamp":1791301575532,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"DOI":"10.1093\/infdis\/jit192","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T00:30:06Z","timestamp":1371688206000},"page":"385-393","source":"Crossref","is-referenced-by-count":437,"title":["Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010"],"prefix":"10.1093","volume":"208","author":[{"given":"Lauri E.","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen F.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steinau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"McQuillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"key\n\t\t\t\t20170702133214_JIT192C1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170702133214_JIT192C2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170702133214_JIT192C3","first-page":"1","article-title":"Quadrivalent Human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR"},{"key":"key\n\t\t\t\t20170702133214_JIT192C4","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR"},{"key":"key\n\t\t\t\t20170702133214_JIT192C5","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males\u2014Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR"},{"key":"key\n\t\t\t\t20170702133214_JIT192C6","first-page":"1117","article-title":"National and state vaccination coverage among adolescents aged 13 through 17\u2013 United States, 2010","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR"},{"key":"key\n\t\t\t\t20170702133214_JIT192C7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170702133214_JIT192C8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"key\n\t\t\t\t20170702133214_JIT192C9","first-page":"S3\/35","article-title":"Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24(","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170702133214_JIT192C10","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2010.02.019","article-title":"Post-licensure monitoring of HPV vaccine in the United States","volume":"28","author":"Markowitz","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170702133214_JIT192C11","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2010.04.070","article-title":"A summary of the post-licensure surveillance initiatives for GARDASIL\/SILGARD","volume":"28","author":"Bonanni","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170702133214_JIT192C12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170702133214_JIT192C15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/infdis\/jir341","article-title":"Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003\u20132006","volume":"204","author":"Hariri","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/infdis\/jir342","article-title":"Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States\u2014National Health And Nutrition Examination Survey, 2003\u20132006: opportunity to measure HPV vaccine impact?","volume":"204","author":"Dunne","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170702133214_JIT192C18","first-page":"1","article-title":"Design and estimation for the National Health Interview Survey, 1995\u20132004","year":"2000","journal-title":"Vital Health Stat 2"},{"key":"key\n\t\t\t\t20170702133214_JIT192C19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2105\/AJPH.81.9.1166","article-title":"Epidemiologic studies utilizing surveys: accounting for the sampling design","volume":"81","author":"Korn","year":"1991","journal-title":"Am J Public Health"},{"key":"key\n\t\t\t\t20170702133214_JIT192C20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/aje\/kwp440","article-title":"Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data","volume":"171","author":"Bieler","year":"2010","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170702133214_JIT192C21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/oxfordjournals.epirev.a036023","article-title":"Assessing vaccine efficacy in the field. Further observations","volume":"10","author":"Orenstein","year":"1988","journal-title":"Epidemiol Rev"},{"key":"key\n\t\t\t\t20170702133214_JIT192C22","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u20132010: Potential impact of human papillomavirus vaccination","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"key\n\t\t\t\t20170702133214_JIT192C23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20170702133214_JIT192C25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key\n\t\t\t\t20170702133214_JIT192C26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20170702133214_JIT192C27","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170702133214_JIT192C28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170702133214_JIT192C29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170702133214_JIT192C30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-0-387-36523-7_3","article-title":"Phylogeny and typing of papillomaviruses","volume-title":"The papillomaviruses","author":"Bernard","year":"2007"},{"key":"key\n\t\t\t\t20170702133214_JIT192C31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/infdis\/jir595","article-title":"Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study","volume":"204","author":"Vaccarella","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiq139","article-title":"Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease","volume":"203","author":"Chaturvedi","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C33","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ejca.2011.10.010","article-title":"Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study","volume":"48","author":"Carozzi","year":"2012","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20170702133214_JIT192C34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jir286","article-title":"Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica","volume":"204","author":"Vaccarella","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170702133214_JIT192C35","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/1055-9965.EPI-05-0465","article-title":"Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections","volume":"14","author":"Chaturvedi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170702133214_JIT192C36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/00333549111260S208","article-title":"Validity of parent-reported vaccination status for adolescents aged 13\u201317 years: National Immunization Survey-Teen, 2008","volume":"126","author":"Dorell","year":"2011","journal-title":"Public Health Rep"},{"key":"key\n\t\t\t\t20170702133214_JIT192C37","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/208\/3\/385\/18069964\/jit192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T05:42:23Z","timestamp":1503553343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jit192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jit192","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718021324.793479097","asserted-by":"object"}]},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8,1]]}}}